| Pre‐index¶ | Post‐index# | |||||||
|---|---|---|---|---|---|---|---|---|
| Number of patients | Mean (SD) monthly all‐ factor consumption, IU | Number of patients | Mean (SD) all‐factor treatment duration, months** | Number of patients | Mean (SD) monthly all‐factor consumption, IU | Number of patients | Mean (SD) all‐factor treatment duration, months** | |
| SHL FVIII†† | 17 | 27,487.4 (33,371.7) | 20 | 9.2 (14.1) | 384 | 20,986.7 (31,390.8) | 457 | 16.0 (18.3) |
| All EHL FVIII | 240 | 24,545.5 (24,997.9) | 251 | 19.9 (14.3) | 305 | 24,649.1 (34,686.9) | 321 | 19.3 (16.9) |
| rFVIIIFc‡‡ | 157 | 52,892.5 (80,220.2) | 164 | 9.3 (8.4) | 197 | 23,915.7 (23,006.8) | 205 | 18.6 (16.7) |
| Emicizumab | 85 | 58,683.5 (88,791.3) | 90 | 15.0 (15.4) | 56 | 20,703.2 (25,506.3) | 56 | 0.6 (1.6) |
EHL, extended half‐life; FVIII, factor VIII; rFVIIIFc, recombinant factor VIII Fc fusion protein; SD, standard deviation; SHL, standard half‐life.
*Pre‐index corresponds to the period ≥12 months before the index date.
†Patients included had pharmacy claims in the pre‐ and post‐index periods and lacked evidence of inhibitors (based on receipt of bypassing agents or evidence of immune tolerance induction, identified as patients receiving 3 times the median factor consumption for their age group for 6 consecutive months [allowing for a 1‐month grace period] during follow‐up).
‡Factor consumption data were not available for all patients; therefore, patient numbers differ between pre‐ and post‐index, as well as between those with reported factor consumption and those with reported treatment duration.
§Factor consumption normalized to patient weight is not included, as limited available data were considered unlikely to produce valid estimates.
¶Pre‐index corresponds to the interval from first observed encounter to initiation of the specified product, excluding date of initiation of the specified product.
#Post‐index corresponds to the interval from initiation of the specified product to the study end date or the patient’s last observed encounter, whichever is earlier.
**Treatment duration based on patients with pharmacy claims.
††No data on factor consumption were available in the pre‐index period for most patients in the SHL group. The remainder were receiving EHL FVIII in the pre‐index period.
‡‡rFVIIIFc is a subgroup of the EHL FVIII group.